Amgen announces positive Phase 3 results for AMG 416 for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease receiving hemodialysis
18 July 2014 | By Amgen
Analysis shows study met primary and all secondary endpoints AMG 416 is a novel calcimimetic administered intravenously...